Suppr超能文献

口服每月伊班膦酸盐对骨质减少症妇女骨微观结构的影响:一项随机安慰剂对照试验。

Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial.

机构信息

INSERM U1033, Université de Lyon, Hôpital E Herriot, Lyon, France.

出版信息

Osteoporos Int. 2013 Jan;24(1):311-20. doi: 10.1007/s00198-012-1947-4. Epub 2012 Mar 9.

Abstract

UNLABELLED

We have examined the effect of oral monthly ibandronate on distal radius and tibia microarchitecture with high-resolution peripheral quantitative tomography compared with placebo, in women with osteopenia, and found that ibandronate did not significantly affect trabecular bone but improved cortical density and thickness at the tibia.

METHODS

We have examined the effect of ibandronate on bone microarchitecture with peripheral high-resolution quantitative computed tomography (HR-pQCT) in a randomized placebo-controlled trial among 148 women with osteopenia. Patients received either oral 150 mg monthly ibandronate or placebo over 24 months. Bone microarchitecture was assessed at baseline, 6, 12, and 24 months, using HR-pQCT at the distal radius and tibia; areal bone mineral density (aBMD) was measured with DXA at the spine, hip, and radius.

RESULTS

At 12 months, there was no significant difference in trabecular bone volume at the radius (the primary end point) between women on ibandronate (10.8 ± 2.5%) and placebo (10.5 ± 2.9%), p = 0.25. There was no significant difference in other radius trabecular and cortical microarchitecture parameters at 12 and 24 months. In contrast, at the tibia, cortical vBMD in the ibandronate group was significantly greater than in the placebo group at 6, 12, and 24 months, with better cortical thickness at 6, 12, and 24 months. With ibandronate, aBMD was significantly increased at the hip and spine at 12 and 24 months but at the radius was significantly superior to placebo only at 24 months. Most of the adverse events related to ibandronate were expected with bisphosphonate use, and none of them were serious.

CONCLUSION

We conclude that 12 months of treatment with ibandronate in women with osteopenia did not affect trabecular bone microarchitecture, but improved cortical vBMD at the tibia at 12 and 24 months, and preserved cortical thickness at the tibia.

摘要

目的

我们通过高分辨率外周定量计算机断层扫描(HR-pQCT)检查了伊班膦酸盐对骨量减少的女性桡骨远端和胫骨微结构的影响,并与安慰剂进行了比较,发现伊班膦酸盐对小梁骨没有显著影响,但改善了胫骨的皮质密度和厚度。

方法

我们在一项骨量减少的女性随机安慰剂对照试验中,通过外周 HR-pQCT 检查了伊班膦酸盐对骨微结构的影响。患者接受了为期 24 个月的每月口服 150mg 伊班膦酸盐或安慰剂治疗。使用 HR-pQCT 在桡骨远端和胫骨处评估基线、6、12 和 24 个月时的骨微结构;使用 DXA 在脊柱、髋部和桡骨处测量面积骨密度(aBMD)。

结果

在 12 个月时,伊班膦酸盐组(10.8±2.5%)和安慰剂组(10.5±2.9%)桡骨的小梁骨体积无显著差异(主要终点),p=0.25。12 和 24 个月时,桡骨其他小梁和皮质微结构参数无显著差异。相比之下,在胫骨处,伊班膦酸盐组的皮质 vBMD 在 6、12 和 24 个月时显著大于安慰剂组,6、12 和 24 个月时皮质厚度也更好。伊班膦酸盐组的髋部和脊柱的 aBMD 在 12 和 24 个月时显著增加,但仅在 24 个月时桡骨的 aBMD 显著优于安慰剂。与伊班膦酸盐相关的大多数不良事件与双膦酸盐的使用有关,且均不严重。

结论

我们的结论是,骨量减少的女性使用伊班膦酸盐治疗 12 个月不会影响小梁骨微结构,但可改善 12 和 24 个月时胫骨的皮质 vBMD,并维持胫骨的皮质厚度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验